## NC-TOPPS ADATC Aftercare Follow-Up Interview

| **Use this form for backup only. Enter data into web-based system. (https://nctopps.ncdmh.net/adatc.htm)   |   |  |  |   |  |   |         |   |         |        |  |
|--|---|--|--|---|--|---|---------|---|---------|--------|--|
| Clinician First Initial & Last Name  |   |  |  |   |  |   |         |   |         |        |  |
|  |   |  |  |   |  |   |         |   |         |        |  |
| Please provide the following information about the individual:   Consumer Record Number (HEARTS #)   Consumer Record Number (HEARTS #)   First three letters of consumer's last name:   (If female, use consumer's maiden name)   First letter of consumer's first name:   Date of Birth:  | time?<br>Hom<br>Hom<br>In yo<br>In fa<br>Ther<br>Publi<br>Priva<br>Halfv<br>Grou<br>Resid<br>Corr<br>Oxfo<br>CAS/<br>CAS/   | (ma.<br>eless<br>eless<br>our or<br>apeur<br>apeur<br>ate Fa<br>way H<br>up Ho<br>dentia<br>ection<br>ord Ho<br>AWOF | rk ond<br>(no f<br>(livir<br>wn hc<br>or frie<br>tic Co<br>cility/J<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>acility/<br>aci | ly one<br>fixed<br>og ten<br>ome/a<br>end's<br>mmu<br>Institu<br>/Institu<br>atme<br>cility | e)<br>addr<br>apart<br>hom<br>nity<br>ution<br>tutio | ess)<br>arily wi<br>ment<br>e/apar<br>(TC)<br>n | th othe | ers)  | ed most | of the |  |
| <ul> <li>1. Were you able to contact the individual by telephone or in-person to complete this interview?</li> <li>□ Yes □ No -&gt; (answer only questions 2 and 3)</li> </ul>   | Other       Deferred         7. Since leaving treatment, which of the following substances have you used?       Deferred  |  |  |   |  |   |         |   |         |        |  |
| 2. Date(s) contact attempted:  | Substance   |  |  |   |  | Past <u>Month</u> - Frequency of Use            |         |   |         |        |  |
|  | (any tob<br>(>=:<br>Less t  | Heav<br>Heav<br>5(4) d<br>han h<br>rijuan  | y alco<br>rinks p<br>eavy a<br>a or ha   | n <i>prod</i> i<br>hol us<br><i>per sit</i><br>alcohol<br>ashish                            | se<br>ting)<br>I use<br>I use                        | Not Used  |         | weekly       Image: | weekly  | Daily  |  |
| ☐ Full-time work (working 35 hours or more a week)   | Fentanyl use  |  |  |   | use  |   |         |   |         |        |  |
| <ul> <li>Part-time work (working less than 35 hours a week)</li> <li>Unemployed (seeking work or on layoff from a job)</li> <li>Not in labor force (not seeking work)</li> <li>Deferred</li> </ul>   | Other I<br>(enter   | Drug l<br>code   | from I   |   |  |   |         |   |         |        |  |
| <ul> <li>5. Since leaving treatment, how often have you participated in</li> <li>a. positive community/leisure activities?</li> <li>Never</li> <li>A few times</li> <li>Deferred</li> <li>b. recovery-related support or self-help groups?</li> <li>Never</li> <li>A few times</li> <li>More than a few times</li> <li>Deferred</li> <li>Deferred</li> <li>Deterred</li> </ul> | Other Drug Codes $5 = Non-prescription Methadone14=Barbiturate57=Spice7=PCP15=Other Sedative or58=Other Prescriptio8=Other HallucinogenHypnoticMeds9=Methamphetamine16=Inhalant59=GHB/GBL10=Other Amphetamine17=Over-the-Counter60=Dilantin11=Other Stimulant22=OxyContin (Oxycodone)61=Cannabinoids12=Benzodiazepine29=MDMA (Ecstasy)13=Other Tranquilizer46=Ketamine8. Did this consumer receive or was expected to receivemethadone treatment?\Box Yes -> (answer b)\Box No -> (skip to 10)b. If 'Yes', what was the last methadone dosage in the 60 daysprior to this aftercare follow-up?(enter zero, if none and skip to 10)mg$ |  |  |   |  |   |         | ion   |         |        |  |

Confidentiality of SUD and MH consumer-identifying information is protected under Federal regulations 42 CFR Part 2 and the Health Insurance Portability and Accountability Act of 1996, P.L. 104-91 (HIPAA) or implementing regulations, 45 CFR Parts 160 and 164. Consumer-identifying information may be disclosed without the individual's consent to the Division of Mental Health, Developmental Disabilities, and Substance Use Services (DMH/DD/SUS) and to its authorized evaluation contractors under the audit or evaluation exeption. Redisclosure of consumer-identifying information without the individual's consent is explicitly prohibited. Your questions may be directed to the NC-TOPPS ADATC Help Desk: nctoppsadatc@ncsu.edu. Sponsored by the NC MH/DD/SUS.

Page 1

Version 07/01/2025

## NC-TOPPS ADATC Aftercare Follow-Up Interview

\*\*Use this form for backup only. Enter data into web-based system. (https://nctopps.ncdmh.net/adatc.htm)

| 9. For dosage level of Methadone greater than zero:<br>Please describe the last methadone dosing:  | 15. If you have a current prescription for psychotropic medications, how often have you taken this medication as                |  |  |  |  |  |
|--|---|--|--|--|--|--|
| $\Box$ Induction –> (skip to 10)   | prescribed?   |  |  |  |  |  |
| $\Box$ Stabilization -> ( <i>skip to 10</i> )  | No prescription   |  |  |  |  |  |
| $\Box$ Taper -> (answer b)   | All or most of the time   |  |  |  |  |  |
| b. If 'Taper', is the methadone withdrawal voluntary or  | ☐ Sometimes   |  |  |  |  |  |
| administrative?  | Rarely or never   |  |  |  |  |  |
| 🗌 Voluntary 🛛 Administrative   | Deferred  |  |  |  |  |  |
| 10. Did this consumer receive or was expected to receive   | 16. Are you currently receiving any of the following treatment in   |  |  |  |  |  |
| buprenorphine (mono or combo products, such as Zubsolv,  | <b>your community for the following?</b> (mark all that apply)  |  |  |  |  |  |
| Suboxone, etc.) treatment?   | Substance Use Disorder  |  |  |  |  |  |
| $\Box$ Yes -> (answer b and c) $\Box$ No -> (skip to 12)   | Mental Health   |  |  |  |  |  |
| b. If 'Yes', how was the buprenorphine administered?   | □Not receiving SUD or MH treatment  |  |  |  |  |  |
| □ Oral (tablets or film) □ Injection   | 17. What barriers, if any, are preventing you from attending  |  |  |  |  |  |
| c. If 'Yes', what was the last buprenorphine dosage in the 60  | outpatient services? (mark all that apply)  |  |  |  |  |  |
| days prior to this aftercare follow-up?  | No barriers to attending outpatient treatment   |  |  |  |  |  |
| mg (enter zero, if none and skip to 12)  | Active mental health symptoms (anxiety or fear, agoraphobia, paranoia, hallucinations)  |  |  |  |  |  |
| 11. For dosage level of Buprenorphine greater than zero:   | Active substance use disorder symptoms (addiction, relapse)   |  |  |  |  |  |
| Please describe the last buprenorphine dosing:   | Physical health problems  |  |  |  |  |  |
| □ Stabilization -> (skip to 12)<br>□ Taper -> (answer b)   | Family or guardian issues (controlling spouse/partner, family illness, child/elder care, domestic violence, family cooperation) |  |  |  |  |  |
| b. If 'Taper', is the buprenorphine withdrawal voluntary or  | Issues with treatment being offered (availability of appropriate  |  |  |  |  |  |
| administrative?  | services, type of treatment wanted by consumer not available,   |  |  |  |  |  |
| □ Voluntary □ Administrative   | engagement issues, service locations, etc. )  |  |  |  |  |  |
| 12. Did this consumer receive or was expected to receive   | Cost or financial reasons   |  |  |  |  |  |
| naltrexone (such as Revia, Vivitrol, etc.) treatment?  | Stigma/Embarrassment  |  |  |  |  |  |
| $\square$ Yes $->$ (answer b and c) $\square$ No $->$ (skip to 14)   | Treatment/Authorization access issues (insurance problems, red  |  |  |  |  |  |
| b. If 'Yes', how was the naltrexone administered? □ Oral □ Injectable  | Lape, etc.)   |  |  |  |  |  |
| $\Box$ Oral $\Box$ Injectable c. If 'Yes', what was the last naltrexone dosage in the 60 days  | Language or communication issues (foreign language issues, lack of  |  |  |  |  |  |
| prior to this aftercare follow-up?   | interpreter, etc.)  |  |  |  |  |  |
| (enter zero, if none and skip to 14)   | Legal reasons (arrest, incarceration)   |  |  |  |  |  |
|  | Transportation issues/Distance to provider  |  |  |  |  |  |
| <ul> <li>13. For dosage level of Naltrexone greater than zero:</li> <li>Please describe the last naltrexone dosing:</li> <li>☐ Induction -&gt; (skip to 14)</li> </ul> | $\square$ Scheduling issues (potential work conflicts, appointment times not working with schedule)                             |  |  |  |  |  |
| $\Box \text{ Stabilization } \rightarrow (skip to 14)$   | □ Lack of stable housing  |  |  |  |  |  |
| $\Box \text{ Taper } -> (answer b)$  | □ NA (not receiving outpatient services)  |  |  |  |  |  |
| b. If 'Taper', is the naltrexone withdrawal voluntary or   |   |  |  |  |  |  |
| administrative?  | 18. Comments/Notes:   |  |  |  |  |  |
| □ Voluntary □ Administrative   |   |  |  |  |  |  |
| 14. Since leaving treatment, how many times  |   |  |  |  |  |  |
| have you been arrested for any offense including   |   |  |  |  |  |  |
| DWI? (enter zero, if none)   |   |  |  |  |  |  |
|  |   |  |  |  |  |  |
| Enter data into web-based system:  |   |  |  |  |  |  |
|  |   |  |  |  |  |  |
| •  |   |  |  |  |  |  |
| https://nctopps.ncdmh.net/adatc.htm  |   |  |  |  |  |  |
| • • • • •  |   |  |  |  |  |  |

## Do not mail this form

Confidentiality of SUD and MH consumer-identifying information is protected under Federal regulations 42 CFR Part 2 and the Health Insurance Portability and Accountability Act of 1996, P.L. 104-91 (HIPAA) or implementing regulations, 45 CFR Parts 160 and 164. Consumer-identifying information may be disclosed without the individual's consent to the Division of Mental Health, Developmental Disabilities, and Substance Use Services (DMH/DD/SUS) and to its authorized evaluation contractors under the audit or evaluation exception. Redisclosure of consumer-identifying information without the individual's consent is explicitly prohibited. Your questions may be directed to the NC-TOPPS ADATC Help Desk: nctoppsadatc@ncsu.edu. Sponsored by the NC MH/DD/SUS.